Published online by Cambridge University Press: 13 August 2018
The inefficiencies of the current pipeline from discovery to clinical approval of drugs demand a surrogate method to indicate adverse drug reactions, e.g. liver damage. Organ-on-chip (OOC) models would be an ideal, rapid, and human-specific alternate, which would render animal testing obsolete. The ground-breaking ability of OOCs and Multi-OOC constructs is the accurate simulation of the in vivo conditions of human organs leading to precise drug screens for cytotoxicity and/or drug efficacy at a faster pace and lesser cost. Here we discuss the innovation, architecture, and the progress of OOCs towards human body-on-a-chip.
This paper is dedicated to Suraj Renugopalakrishnan.
Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between 13th August 2018 - 2nd March 2021. This data will be updated every 24 hours.